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INTRODUCTION
Mucinous carcinoma (MC) of the breast is not a common
disease and the incidence of MC was reported to range from
1% to 6% of all primary breast cancers (1-4). MC of the breast
was characterized by a large amount of mucin production and
in general, defined as having a mucinous component of 50%
or more (5, 6). Those lesions had different features from inva-
sive ductal carcinoma-not otherwise specified (IDC-NOS).
MC usually occurs in postmenopausal women. Median age
at diagnosis was older than 60 and older than that of IDC-
NOS (4, 6). Furthermore, MC showed more favorable clini-
copathological characteristics, such as lower incidence of nodal
metastasis, higher expression of estrogen and progesterone
receptors, and differentiated grade (2, 6, 7). Therefore, prog-
nosis of MC is better than that of IDC-NOS with 10-yr sur-
vival rates better than 80% (1, 8).
Histologically MC is classified into 2 subgroups based on
the degree of cellularity, which are pure type and mixed muci-
nous-ductal type (9). However, cut-off values of the mucinous
component for defining pure type MC was not standardized,
and later, others divided MC into type A and type B (10). The
former is the classical type with large amounts of mucins and
the latter is a variant type with neuroendocrine differentia-
tion or feature of signet ring cells (5, 10).
Prognostic significance of clinicopathological characteris-
tics in MC patients is not well established, because of its low
incidence rate and lack of a standard definition. Treatment
guidelines for MC are mostly extrapolated from data based
on invasive ductal carcinoma (IDC) without clear validation.
As incidence of breast cancer was significantly increasing in
Korea (11, 12), it was necessary to investigate incidence rates,
clinicopathological characteristics, and prognosis of MC to
prepare an adequate treatment guideline. But there are few
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Clinicopathological Characteristics of Mucinous Carcinoma of the Breast
in Korea: Comparison with Invasive Ductal Carcinoma-Not Otherwise
Specified
Clinicopathological characteristics and prognostic factors of mucinous carcinoma
(MC) were compared with invasive ductal carcinoma-not otherwise specified (IDC-
NOS). Clinicopathological characteristics and survivals of 104 MC patients were
retrospectively reviewed and compared with those of 3,936 IDC-NOS. The median
age at diagnosis was 45 yr in MC and 47 yr in IDC-NOS, respectively. The sensitiv-
ity of mammography and sonography for pure MC were 76.5% and 94.7%, respec-
tively. MC showed favorable characteristics including less involvement of lymph node,
lower stage, more expression of estrogen receptors, less HER-2 overexpression
and differentiated grade, and better 10-yr disease-free survival (DFS) and overall
survival (OS) (86.1% and 86.3%, respectively) than IDC-NOS (74.7% and 74.9%,
respectively). Ten-year DFS of pure and mixed type was 90.2% and 68.8%, respec-
tively. Nodal status and stage were statistically significant factors for survival. MC
in Koreans showed similar features to Western populations except for a younger
age of onset than in IDC-NOS. Since only pure MC showed better prognosis than
IDC-NOS, it is important to differentiate mixed MC from pure MC. Middle-aged Kore-
an women presenting breast symptoms should be examined carefully and evalu-
ated with an appropriate diagnostic work-up because some patients present radio-
logically benign-like lesions.
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studies on MC and information is limited. In this study, we
investigated the clinicopathological characteristics and treat-
ment patterns for MC and compared survivals of MC with
those of IDC-NOS. We evaluated the impact of those param-
eters on outcomes of MC.
MATERIALS AND METHODS
We retrospectively reviewed the data of 4,932 breast can-
cer patients who were treated at the Department of Surgery,
Yonsei University College of Medicine in Seoul, Korea bet-
ween January 1986 and December 2006. Of them, 104 pati-
ents (2.1%) were diagnosed with MC. These patients were
compared with 3,936 patients with IDC-NOS who were treat-
ed during the same period. Pathologic slides of 74 patients
were available and breast pathologists reviewed their slides.
However, slides of the remaining 30 patients were not avail-
able and we reviewed these cases through previous patholog-
ic reports. Pure type MC was defined as having a mucinous
component of more than 90% and specialized pathologists
with extensive experience in breast pathology performed a
pathologic slide review. Sixty-one (82.4%) of 74 patients were
categorized as having pure type MC.
Data regarding patient demographics, histopathology of
primary tumor, treatment patterns, and survivals were ob-
tained by reviewing medical records. Patients were treated
with either mastectomy or lumpectomy and axillary lymph
node dissection or sentinel lymph node biopsy with local radio-
therapy. After completion of surgery, adjuvant treatments were
administered as indicated based on international guidelines.
Tumor stage was based on the 6th American Joint Commit-
tee on Cancer (AJCC) criteria. Histological type and grading
followed the World Health Organization (WHO) classifica-
tion. Ten percent or more of positively stained cells was used
as the cut-off for estrogen receptor (ER) and progesterone recep-
tor (PR) positivity. HER-2/neu staining was scored from 0
to 3+ according to the guideline suggested for HercepTestTM
(DAKO, Glostrup, Denmark) (13). HER-2/neu immuno-
histochemical staining was considered positive when strong
(3+) membranous staining was observed, whereas cases with
0 to 1+were regarded as negative. Because fluorescent in-situ
hybridization test had not been performed routinely, cases
with equivocal (2+) staining were excluded in statistical anal-
yses. Clinical follow-up included history taking, physical exam-
ination, laboratory tests and radiologic imaging every 6-12
months.
The differences between the 2 groups were evaluated by
chi-square test. Survival curves were determined and plot-
ted using the Kaplan-Meier method and group differences
in survival time were investigated by log-rank test. P values
less than 0.05 was considered statistically significant. SPSS
for Windows (version 13.0, SPSS Inc., Chicago, IL, USA) was
used for all statistical analyses.
RESULTS
Clinicopathological characteristics and treatment patterns
of all patients are summarized in Table 1. Median age at diag-
nosis was 47 yr in all patients (range, 20-93 yr), and age at
diagnosis was much younger in MC patients than in IDC-
NOS patients with statistical significance (P=0.022); 45 yr
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IDC-NOS, invasive ductal carcinoma-not otherwise specified; BCS, breast-
ing-conserving surgery.
Characteristics
IDC-NOS
(%)
Mucinous 
carcinoma (%)
P value
Age (yr, n=4,040) 0.022 
≤50 2,483 (63.1) 77 (74.0)
>50 1,453 (36.9) 27 (26.0)
T stage (n=4,025) 0.682
T1 1,839 (46.9) 44 (42.3)
T2 1,838 (46.9) 53 (51.0)
T3 177 (4.5) 6 (5.8)
T4 67 (1.7) 1 (1.0)
N stage (n=4,028) 0.000 
N0 2,125 (54.2) 85 (81.7)
N1 1,011 (25.8) 12 (11.5)
N2 477 (12.2) 6 (5.8)
N3 311 (7.9) 1 (1.0)
TNM stage (n=4,027) 0.005 
Stage I 1,250 (31.9) 41 (39.4)
Stage II 1,823 (46.5) 54 (51.9)
Stage III 850 (21.7) 9 (8.7)
Estrogen receptor (n=3,416) 0.008 
Negative 1,218 (36.6) 20 (22.7)
Positive 2,110 (63.4) 68 (77.3)
Progesterone receptor 0.295
(n=3,353)
Negative 1,385 (42.4) 32 (36.8)
Positive 1,881 (57.6) 55 (63.2)
HER-2/neu (n=2,258) 0.005 
Negative 1,538 (70.3) 60 (85.7)
Positive 650 (29.7) 10 (14.3)
Histologic grade (n=3,065) 0.000 
I 684 (22.9) 63 (79.7)
II/III 2,302 (77.1) 16 (20.3)
Operation methods (n=4,037) 0.229
BCS 899 (22.9) 29 (27.9)
Mastectomy  3,034 (77.1) 75 (72.1)
Chemotherapy (n=3,960) 0.097
Not done 1,108 (28.7) 37 (36.3)
Done 2,750 (71.3) 65 (63.7)
Hormone therapy (n=3,871) 0.056
Not done 1,644 (43.6) 34 (34.0)
Done 2,127 (56.4) 66 (66.0)
Radiotherapy (n=3,852) 0.672
Not done 2,348 (62.6) 64 (64.6)
Done 1,405 (37.4) 35 (35.4)
Table 1. Clinicopathological characteristics and treatment pat-
terns of all patients
old for MC patients and 47 yr old for IDC-NOS patients.
Among 74 patients whose slides were available for review-
ing, 61 patients (82.4%) were pure MC and 13 (17.6%) were
mixed mucinous-ductal carcinoma. Mammographic and sono-
graphic findings according to Breast Imaging Reporting and
Data System (BI-RADS) category were investigated. Mam-
mographic and sonographic findings were available in 21 and
38 pure MC patients, respectively and 5 and 5 mixed type
MC, respectively (Table 2). In pure type MC, sensitivity of
mammography and sonography was 76.5% and 94.7%, res-
pectively. However, in mixed MC, the sensitivity of mam-
mography and sonography was 100% in both modalities.
Eighty-five (81.7%) of 104 MC patients had no axillary
lymph node involvement and more MC patients had lower
tumor stage than IDC-NOS patients (P=0.000 and 0.005,
respectively). Expressions of ER and PR were higher in MC
than in IDC-NOS; 77.3% and 63.2%, respectively, but ER
only showed a statistical significance (P=0.008). Of the 70
patients whose status of HER-2/neu was available, only 10
(14.3%) showed HER-2/neu overexpression. MC showed a
favorable histologic grade. Tumor size and treatments pat-
terns including operation methods, adjuvant chemotherapy,
hormonal therapy, and radiation therapy were not statistical-
ly different from IDC-NOS, but less chemotherapy and more
hormone therapy were applied to MC patients due probably
to more favorable histologic features associated with higher
ER expression in MC. Clinicopathological characteristics and
treatment patterns of pure MC patients are similar to those
with the mixed type except tumor size, histologic grade, and
radiation therapy (Table 3). More pure MC patients had small-
er in size and differentiated histologic grade than mixed type.
More radiation therapy was applied to pure MC because more
pure MC patients received breast-conserving surgery.
The median follow-up duration was 63.5 months in all
patients (range, 0-262 months). There were 9 disease relaps-
es and 6 deaths during follow-up in MC and 5- and 10-yr
disease-free survival (DFS) rates were 93.3% and 86.1%, res-
pectively (Fig. 1A). Five- and 10-yr overall survival (OS) rates
were 93.5% and 86.3%, respectively (Fig. 1B). Ten-year DFS
and OS rates of IDC-NOS were 74.7% and 74.9%, respec-
tively. MC showed better survival outcomes than IDC-NOS
with statistical significance (Fig. 1, P=0.012 for DFS and
0.005 for OS). In pure MC, the 10-yr DFS and OS rates were
90.2% and 91.3%, respectively and 10-yr DFS and OS rates
of the mixed type were 68.8% and 100%, respectively. DFS
and OS rates were not statistically different between pure and
mixed types (Fig. 2, P=0.360 and 0.374, respectively) due
probably to the small sample size. Univariate analysis for DFS
and OS according to clinicopathological characteristics in MC
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BI-RADS, Breast imaging-reporting and data system; MC, mucinous car-
cinoma.
BI-RADS category
Pure type MC
Mammog-
raphy
(n=21, %)
Sonog-
raphy
(n=38, %)
Mixed type MC
Mammog-
raphy
(n=5, %)
Sonog-
raphy
(n=5, %)
0 (Incomplete) 4 (19.0) 0 0 0
1 (Normal) 1 (4.8) 0 0 0
2 (Benign) 1 (4.8) 0 0 0
3 (Probably benign) 2 (9.5) 2 (5.3) 0 0
4 (Suspicious 5 (23.8) 23 (60.5) 0 0
abnormality)
5 (Highly suggestive 8 (38.1) 13 (34.2) 5 (100) 5 (100)
of malignancy)
Table 2. Radiologic findings according to breast imaging-report-
ing and data system
MC, mucinous carcinoma; BCS, breast-conserving surgery.
Characteristics
Pure type
MC (%)
Mixed type
MC (%)
P value
Age (yr, n=74) 0.928 
≤50 43 (70.5) 9 (69.2)
>50 18 (29.5) 4 (30.8)
Tumor size (n=74) 0.042
≤2 cm 28 (45.9) 2 (15.4)
>2 cm 33 (54.1) 11 (84.6)
N stage (n=74) 0.462 
N0 48 (78.7) 9 (69.2)
N1-3 13 (21.3) 4 (30.8)
TNM stage (n=74) 0.113 
Stage I 25 (41.0) 2 (15.4)
Stage II 31 (50.8) 8 (61.5)
Stage III 5 (8.2) 3 (23.1)
Estrogen receptor (n=71) 0.959 
Negative 13 (22.4) 3 (23.1)
Positive 45 (77.6) 10 (76.9)
Progesterone receptor (n=71) 0.479
Negative 24 (41.4) 4 (30.8)
Positive 34 (58.6) 9 (69.2)
HER-2/neu (n=60) 0.215 
Negative 43 (86.0) 7 (70.0)
Positive 7 (14.0) 3 (30.0)
Histologic grade (n=73) 0.000 
I 59 (96.7) 1 (8.3)
II/III 2 (3.3) 11 (91.7)
Operation methods (n=74) 0.148
BCS 22 (36.1) 2 (15.4)
Mastectomy  39 (63.9) 11 (84.6)
Chemotherapy (n=73) 0.407
Not done 21 (35.0) 3 (23.1)
Done 39 (65.0) 10 (76.9)
Hormone therapy (n=71) 0.835
Not done 15 (25.9) 3 (23.1)
Done 43 (74.1) 10 (76.9)
Radiotherapy (n=70) 0.035
Not done 30 (52.6) 11 (84.6)
Done 27 (47.4) 2 (15.4)
Table 3. Clinicopathological characteristics and treatment pat-
terns of mucinous carcinoma patients available for slides review
revealed that lymph node status and tumor stage were statis-
tically significant factors for survival (Table 4).
In stage-matched analysis for OS, MC showed a trend to-
ward better survival than IDC-NOS (Fig. 3), but only the
stage II group showed statistical significance. This was prob-
ably due to the small sample size and short follow-up dura-
tion. In age-matched analysis for OS, MC showed a better
survival rate than IDC-NOS in the patient group whose age
was 50 or younger (Fig. 4). Among MC patients whose pathol-
ogy slide was available for reviewing, survivals of MC accord-
ing to the subtype were compared with IDC-NOS (Fig. 2A,
B). Pure MC showed a better DFS than IDC-NOS (P=0.037)
and there was similar DFS patterns between mixed type MC
and IDC-NOS (P=0.795). Pure MC showed a better OS than
IDC-NOS (P=0.049) but differences of OS between the mixed
type and IDC-NOS did not reach statistical significance in
our study (P=0.143).
DISCUSSION
Incidence of breast cancer in Korea has significantly been
increasing in recent years. It accounted for 16.8% of all female
cancers in 2002 and incidence of breast cancer in Korean wo-
men is anticipated to increase (11, 14, 15). Besides incidence,
the percentage of early-stage breast cancer has steadily in-
creased (16). Screening mammography and use of ultrasonog-
raphy play an important role in detection of breast cancers
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Fig. 1. Survival curves in all patients. (A) Disease-free survival curve according to histologic type. (B) Overall survival curves according to
histologic type.
IDC-NOS, Invasive ductal carcinoma-not otherwise specified.
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Fig. 2. Survival curves of mucinous carcinoma patients available for histologic subtype. (A) Disease-free survival curve compared with IDC-
NOS. (B) Overall survival curve compared with IDC-NOS.
MC, Mucinous carcinoma; IDC-NOS, Invasive ductal carcinoma-not otherwise specified.
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Fig. 3. Stage-matched overall survival curves in all patients. (A) Stage
I, (B) Stage II, (C) Stage III.
IDC-NOS, Invasive ductal carcinoma-not otherwise specified.
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Fig. 4. Age-matched overall survival curves in all patients. (A) Age of 50 yr or younger, (B) Age over 50 yr.
IDC-NOS, Invasive ductal carcinoma-not otherwise specified.
in earlier stages (17). Since 1996, it was recommended that
all Korean women over 40 yr old underwent a mammogra-
phy every 1 or 2 yr (18). From 1996 to 2004, the incidence
of stage 0 and I breast cancers increased remarkably by 128.6%
and 81.6%, respectively (16). However, because of the low
incidence rate and small number of studies on specific type of
breast cancer including MC, limited information is available
regarding epidemiology, clinical, radiological and patholog-
ical features, risk factors, and prognosis. It is necessary to inves-
tigate incidence rate, clinicopathological characteristics, and
prognosis of MC to prepare an adequate treatment guideline.
Most MC patients complained palpable mass in their breast,
and radiologically it frequently mimics a benign lesion (19).
Pure MC especially appears as a well-defined mass lesion but
the mixed type shows an indistinct or microlobulated pattern
(20, 21). Although image study findings were only available
in a small number of patients, 23.5% of pure MC cases had
false negative findings in mammography but ultrasonogra-
phy showed much better sensitivity at 94.7%. Among pati-
ents available in ultrasonographic findings, most were suspi-
cious abnormalities or highly suspicious of malignancy. These
radiologically benign lesion-like characteristics of MC some-
times cause a delay in diagnosis (19). Physicians must under-
stand the limits of screening mammography because the peak
age of incidence in Korean breast cancer patients is in the 40s
(16) and the sensitivity of mammography for premenopausal
women is quite low (22-24). Middle-aged women present-
ing breast symptoms should be examined carefully and ultra-
sonography may be helpful.
Many Western studies reported that MC had more favor-
able pathological characteristics than IDC-NOS (1-4, 6, 7).
They were smaller in tumor size, less axillary lymph node
involvement, more expression rates of ER and PR, lower grade,
lower proliferation rates and less overexpression of HER-2/
neu. Another characteristic of MC was that it usually occurr-
ed in postmenopausal women (2, 4, 6), and their age at diag-
nosis ranged from 65 to 71 yr and older than that of IDC-
NOS ranged from 59 to 61 yr (3, 6). These favorable features
of MC led to better survival rates than IDC-NOS. The 10-yr
OS of MC was reported at more than 80% (4, 6, 7).
In our study, the median age of MC patients was younger
than IDC-NOS patients. The median age of our study pop-
ulation was not different from that of Korean breast cancer
patients and another study reported the mean age of MC and
IDC-NOS at 45.5 and 46.9 yr, respectively, which was sim-
ilar to our results (12, 25). Therefore, the age of onset is quite
different from that of Western MC cases. The reason for the
younger age of onset in Korean women is not clear, but it
might be partly due to wide use of ultrasonography, genetic
or environmental factors, a cohort effect of high incidence in
the younger generation or relatively easier accessibility to
detect breast cancer among middle-aged women (15). How-
ever, histological features and survival rates of MC patients
were similar to those of Western patients. Lymph node sta-
tus was the most significant factor for survival.
MC of the breast is not a homogeneous entity and was divid-
ed into pure and mixed types (5, 10). Pure MC was associat-
ed with better survival rates than the mixed type, but survival
rates of mixed type were not different from those found in
IDC-NOS (2, 26, 27). Among 74 available patients with his-
tologic subtype, there were no differences in DFS and OS bet-
ween pure and mixed MC. This was probably due to the small
sample size and short follow-up duration, and larger data sam-
ples with longer follow-up would be necessary to confirm
these differences. Because age distribution was different bet-
ween MC and IDC-NOS, we compared survival matched by
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DFS, disease-free survival; OS, overall survival; BCS, breasting-conserv-
ing surgery.
Characteristics 5-yr DFS P value 5-yr OS P value
Age (yr) 0.939 0.385
≤50 (n=77) 92.8 94.5
>50 (n=27) 95.2 90.9
T stage 0.074 0.874
≤2 cm (n=44) 97.4 93.3
>2 cm (n=60) 90.5 93.2
N stage 0.026 0.030
Negative (n=85) 96.1 95.8
Positive (n=19) 80.5 81.8
TNM stage 0.010 0.003
Stage I (n=41) 97.3 93.1
Stage II (n=54) 95.9 98.1
Stage III (n=9) 64.8 71.4
Estrogen receptor 0.842 0.930
Negative (n=20) 88.2 94.1
Positive (n=68) 95.5 92.4
Progesterone receptor 0.869 0.419
Negative (n=32) 89.7 96.3
Positive (n=55) 96.3 89.6
HER-2/neu 0.208 -
Negative (n=60) 95.7 100
Positive (n=10) 88.9 100
Histologic grade 0.057 0.617
I (n=63) 96.5 94.7
II/III (n=16) 86.7 88.9
Operation methods 0.228 0.161
BCS (n=29) 100 100
Mastectomy (n=75) 90.7 91.1
Chemotherapy 0.063 0.751
Not done (n=37) 100 93.9
Done (n=65) 89.2 92.5
Hormone therapy 0.871 0.112
Not done (n=34) 93.2 90.2
Done (n=66) 95.1 97.1
Radiotherapy 0.737 0.417
Not done (n=64) 96.5 96.4
Done (n=35) 93.1 95.5
Table 4. Univariate analysis for disease-free survival and overall
survival of patients with mucinous carcinoma
age. In patients whose age was 50 yr or less, MC showed bet-
ter survival than IDC-NOS (P=0.008). There was a similar
trend in patient groups older than 50 yr, although it was not
statistically significant (P=0.349). Some Western studies re-
ported that age at diagnosis of MC was a significant prognos-
tic factor (4, 6). This may be related to the older onset age in
Western MC patients.
In summary, mucinous carcinoma shows more favorable
histologic features and better prognosis than IDC-NOS. How-
ever, Korean MC developed at younger ages than IDC-NOS.
Since only pure MC showed better prognosis than IDC-NOS,
it is important to differentiate mixed MC from pure MC.
Patients with mixed MC might be treated as guidelines for
IDC. In pure MC patients with favorable risk factors, how-
ever, adjuvant chemotherapy might be more saved. MC clin-
ically and radiologically mimics a benign lesion and this may
lead to a delay in diagnosis. Therefore, middle-aged Korean
women presenting a palpable mass should be examined careful-
ly and the appropriate diagnostic procedures such as ultrasonog-
raphy are warranted for early detection of malignant tumors.
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